Immune monitoring of SARS-CoV-2-specific T cell and B cell responses in patients with multiple sclerosis treated with ocrelizumab
DiscussionOur results call for a critical discussion regarding appropriate vaccination intervals and potential biomarkers for the prediction of (re)infection with SARS-CoV-2 in patients with MS receiving ocrelizumab.Unique identifierDRKS00029110; URL: http://apps.who.int/trialsearch/.
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
More News: Allergy & Immunology | Chemistry | Coronavirus | Covid Vaccine | COVID-19 | Multiple Sclerosis | Pandemics | Respiratory Medicine | SARS | Study | Vaccines